Plus therapeutics reports first quarter 2023 financial results and business highlights

Plus completes phase 1/part a of the respect-lm trial management to host conference call today at 5:00 p.m. et austin, texas, april 20, 2023 (globe newswire) --  plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended march 31, 2023, and provided an overview of recent business highlights.
PSTV Ratings Summary
PSTV Quant Ranking